Madrigal Pharmaceuticals (MDGL) Cash from Financing Activities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash from Financing Activities data on file, last reported at $2.3 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $2.3 million, down 73.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $249.7 million (up 46.87% YoY), and the FY2025 annual result was $256.0 million, down 65.18% from the prior year.
• Cash from Financing Activities slipped to $2.3 million in Q1 2026 per MDGL's latest filing, from $9.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $573.7 million in Q1 2024 and troughed at $1.7 million in Q2 2025.
• A 5-year average of $126.8 million and a median of $42.9 million in 2023 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 3071.36% in 2025 and fell as far as 98.7% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $264.3 million in 2022, then soared by 81.55% to $479.9 million in 2023, then sank by 95.88% to $19.8 million in 2024, then slumped by 54.7% to $9.0 million in 2025, then sank by 74.0% to $2.3 million in 2026.
• Business Quant data shows MDGL's Cash from Financing Activities at $2.3 million in Q1 2026, $9.0 million in Q4 2025, and $236.6 million in Q3 2025.